Marché mondial du syndrome des anticorps antiphospholipides – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché du syndrome des anticorps antiphospholipides

Le marché mondial du syndrome des anticorps antiphospholipides devrait connaître une croissance significative au cours de la période de prévision. La population vieillissante et vulnérable et la forte demande de médicaments sont quelques-uns des facteurs qui influent sur la croissance du marché du syndrome des anticorps antiphospholipides. De nombreux acteurs majeurs du marché contribuent grandement à la découverte et au développement de médicaments. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché mondial du syndrome des anticorps antiphospholipides au cours de la période de prévision 2022-2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Définition du marché

Le syndrome des anticorps antiphospholipides, également appelé syndrome de Hughes, est une maladie auto-immune rare caractérisée par une thrombose artérielle ou veineuse récurrente, la présence d'anticorps antiphospholipides circulants et une morbidité liée à la grossesse. Il se rencontre principalement chez les femmes et peut survenir comme une maladie unique ou être associé au lupus érythémateux disséminé. Il revêt une grande importance pour le secteur de la santé et devrait donc connaître une forte augmentation au cours de la période de prévision.

Portée du rapport et segmentation du marché

Global Antiphospholipid Antibody Syndrome Market Dynamics

Drivers

• Rising Awareness For Disease Treatment

Rising awareness among patients and healthcare professionals for treating different types of antiphospholipid antibody syndrome and more and more usage of combination therapy are the driving factors expected to boost the demand for global antiphospholipid antibody syndrome market during the forecast period of 2022-2029.

• Increasing Prevalence of Antiphospholipid Antibody Syndrome

As per a study conducted by García et. al. in 2019, the annual estimated incidence rate of antiphospholipid antibody syndrome was 50 per 100,000 population. In addition to this, as per the study conducted by D'Cruz et. al. in 2019, incidence of the syndrome in the U.K. rise high at 50 in females in 2011 and 9.8 per 100,000 in males in 2012. This boosts the market growth.

Opportunities

• Increasing Demand for Retail Pharmacies

The rise in the number of antiphospholipid antibody syndrome therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global antiphospholipid antibody syndrome market over a forecast period.

• High Cost

The huge expenditure of the treatment methods surely hamper the market growth.

This global antiphospholipid antibody syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antiphospholipid antibody syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Antiphospholipid Antibody Syndrome Market

The covid-19 pandemic negatively impacted the global antiphospholipid antibody syndrome market because the utmost priority was given to Covid-19 patients for treatment. Several medical colleges and hospitals were reorganised and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. Discovery and development of drugs for the types of metabolic syndromes also slowed down during the pandemic, but surely it wasn’t in a pause and now in the post pandemic era, it is rising again.

Global Antiphospholipid Antibody Syndrome Market Scope

The global antiphospholipid antibody syndrome market is segmented on the basis of disease type, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Anticoagulants
• NSAIDS
• Others

Route of Administration

• Oral
• Parental
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Antiphospholipid Antibody Syndrome Market Regional Analysis/Insights

The global antiphospholipid antibody syndrome market is analysed and market size insights and trends are provided by disease type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global antiphospholipid antibody syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of refined healthcare expenditure and increased patient awareness level.

Asia-Pacific dominates the market due to the availability of broad range of therapeutics and favourable regulatory guidelines

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Antiphospholipid Antibody Syndrome Market Share Analysis

Le paysage concurrentiel du marché mondial du syndrome des anticorps antiphospholipides fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial du syndrome des anticorps antiphospholipides.

Les principaux acteurs opérant sur le marché mondial du syndrome des anticorps antiphospholipides comprennent :

• Novartis SA (Suisse)
• Fresenius Kabi AG (Allemagne)
• Akorn Incorporated (États-Unis)
• Mylan NV (États-Unis)
• Johnsons & Johnsons Services Inc (États-Unis)
• F. Hoffman-La Roche SA (Suisse)
• Lilly (États-Unis)
• Merck & Co., Inc. (États-Unis)
• Aurobindo Pharma (Inde)
• Shenzhen Techdow Pharmaceutical Co., Ltd (Chine)
• Bayer AG (Allemagne)
• Teva Pharmaceuticals Industries Ltd. (Israël)
• Lilly (États-Unis)
• AstraZeneca (Royaume-Uni)

SKU-53904